Is Pfizer Stock Underperforming the S&P 500?

Pfizer Inc., a multinational pharmaceutical and biotechnology company headquartered in New York, specializes in the discovery, development, manufacturing, and distribution of medicines and vaccines. With a market capitalization of $159.4 billion, Pfizer falls into the large-cap category, indicating its significant influence and size within the pharmaceutical industry.

The company's innovative drug pipeline and diverse range of products, including treatments for various therapeutic areas, contribute to its strong market standing.

Despite outperforming the S&P 500 (SPX) in recent months, Pfizer's stock has underperformed in the past year. As of the latest data, Pfizer's shares are trading 2.7% below their 52-week high, which was $28.75 on April 2, 2026. Nevertheless, Pfizer's stock has shown impressive growth, with a 12.3% increase year-to-date and a 13.7% rise over the past 52 weeks. In comparison, the S&P 500 has gained 12.7% YTD and 18.6% over the past year.

Analysts' consensus is generally positive, with a Moderate Buy rating assigned to Pfizer. The mean price target among the 28 analysts covering the stock is $28.60, suggesting a slight upside potential of 2.3% from its current trading price. However, the company's performance has been overshadowed by competitors like Eli Lilly and Company (LLY), which has experienced more substantial growth, up by 9.3% in 2026 and 60.5% over the past year.

Analysts have cited Pfizer's reliance on aging blockbuster drugs, declining revenues stemming from the COVID-19 pandemic, and upcoming patent expirations as factors contributing to its underperformance.